Topical resiquimod: a promising adjuvant for vaccine development?

References

• Chang BA, Cross JL, Najar HM, Dutz JP. Topical resiquimod promotes priming of CTL to parenteral antigens. Vaccine27(42), 5791–5799 (2009).
   PubMed Web of Science ®Google Scholar
• Aguilar JC, Rodriguez EG. Vaccine adjuvants revisited. Vaccine25(19), 3752–3762 (2007).
   PubMed Web of Science ®Google Scholar
• Perrie Y, Mohammed AR, Kirby DJ, McNeil SE, Bramwell VW. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int. J. Pharm.364(2), 272–280 (2008).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, De Gregorio E. The path to a successful vaccine adjuvant – “The long and winding road”. Drug Discov. Today14(11/12), 541–551 (2009).
   PubMed Web of Science ®Google Scholar
• Tritto E, Mosca F, De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine27(25–26), 3331–3334 (2009).
   PubMed Web of Science ®Google Scholar
• Lambrecht BN, Kool M, Willart MAM, Hammad H. Mechanism of action of clinically approved adjuvants. Curr. Opin. Immunol.21(1), 23–29 (2009).
   PubMed Web of Science ®Google Scholar
• Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr. Top. Microbiol. Immunol.311, 17–58 (2006).
   PubMed Web of Science ®Google Scholar
• Manicassamy S, Pulendran B. Modulation of adaptative immunity with Toll-like receptors. Semin. Immunol.21, 185–193 (2009).
   PubMed Web of Science ®Google Scholar
• Tacken PJ, Torensma R, Figdor CG. Targeting antigens to dendritic cells in vivo. Inmmunobiology211, 599–608 (2006).
   PubMed Web of Science ®Google Scholar
• Hou B, Reizis B, DeFranco AL. Toll-like receptors activate innate and adaptive immunity by using dendritic cell-intrinsic and -extrinsic mechanisms. Immunity29(2), 272–282 (2008).
   PubMed Web of Science ®Google Scholar
• Garlapati S, Facci M, Polewicz M et al. Strategies to link innate and adaptive immunity when designing vaccine adjuvants. Vet. Immunol. Immunopathol.128(1–3), 184–191 (2009).
   PubMed Web of Science ®Google Scholar
• Lahiri A, Das P, Chakravortty D. Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond. Vaccine26(52), 6777–6783 (2008).
   PubMed Web of Science ®Google Scholar
• Johnston D, Bystryn JC. Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine. Vaccine24(11), 1958–1965 (2006).
   PubMed Web of Science ®Google Scholar
• Meyer T, Stockfleth E. Clinical investigations of Toll-like receptor agonists. Expert Opin. Investig. Drugs17(7), 1051–1065 (2008).
   PubMed Web of Science ®Google Scholar
• Tomai MA, Miller RL, Lipson KE, Vasilakos JP, Woulfe SL. Immune response modifiers: imiquimod and future drugs for modulating the immune response. Drug Discov. Today3, 343–352 (2006).
   Google Scholar
• Tomai MA, Miller RL, Lipson KE et al. Resiquimod and other immune response modifiers as vaccine adjuvants. Expert Rev. Vaccines6(5), 835–847 (2007).
   PubMed Web of Science ®Google Scholar
• Klinman DM. Adjuvant activity of CpG oligodeoxynucleotides. Int. Rev. Immunol.25(3–4), 135–154 (2006).
   PubMed Web of Science ®Google Scholar
• Najar HM, Dutz JP. Topical TLR9 agonists induce more efficient cross-presentation of injected protein antigen than parenteral TLR9 agonists do. Eur. J. Immunol.37, 2242–2256 (2007).
   PubMedGoogle Scholar
• Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv. Drug Deliv. Rev.61(3), 195–204 (2009).
   PubMed Web of Science ®Google Scholar
• Otero M, Calarota SA, Felber B et al. Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model. Vaccine22(13–14), 1782–1790 (2004).
   PubMed Web of Science ®Google Scholar
• Thomsen LL, Topley P, Daly MG, Brett SJ, Tite JP. Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine22(13–14), 1799–1809 (2004).
   PubMed Web of Science ®Google Scholar
• Weeratna RD, Makinen SR, McCluskie MJ, Davis HL. TLR agonists as vaccine adjuvants: comparison of CpG ODN and resiquimod (R-848). Vaccine23(45), 5263–5270 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang W, Matlashewski G. Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice. Infect. Immun.76(8), 3777–3783 (2008).
   PubMed Web of Science ®Google Scholar
• Rechtsteiner G, Warger T, Osterloh P, Schild H, Radsak MP. Priming of CTL by transcutaneous peptide immunization with imiquimod. J. Immunol.174(5), 2476–2480 (2005).
   PubMed Web of Science ®Google Scholar
• Othoro C, Johnston D, Lee R, Soverow J, Bystryn J, Nardin E. Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod. Infect. Immun.77(2), 739–748 (2009).
   PubMedGoogle Scholar
• Wilson NS, Behrens GM, Lundie RJ et al. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat. Immunol.7(2), 165–172 (2006).
   PubMed Web of Science ®Google Scholar
• Le Bon A, Durand V, Kamphuis E et al. Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming. J. Immunol.176(8), 4682–4689 (2006).
   PubMed Web of Science ®Google Scholar
• Perry JA, Olver CS, Burnett RC, Avery AC. Cutting edge: the acquisition of TLR tolerance during malaria infection impacts T cell activation. J. Immunol.174(10), 5921–5925 (2005).
   PubMed Web of Science ®Google Scholar
• Kamphuis E, Junt T, Waibler Z, Forster R, Kalinke U. Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood108(10), 3253–3261 (2006).
   PubMed Web of Science ®Google Scholar
• Gunzer M, Riemann H, Basoglu Y et al. Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletion. Blood106(7), 2424–2432 (2005).
   PubMed Web of Science ®Google Scholar
• Sauder DN, Smith MH, Senta-McMillian T, Soria I, Meng T. Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults. Antimicrob. Agents Chemother.47(12), 3846–3852 (2003).
   PubMed Web of Science ®Google Scholar